Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Recombinant Human Plasma Gelsolin for Moderate-to-Severe ARDS
2023-510109-16-00Phase 2Authorised
- Sponsor
- BioAegis Therapeutics
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing Recombinant human plasma gelsolin + standard of care with Placebo + standard of care (2 arms). Primary endpoint: All-cause mortality at Day 28. Planned start Nov 2024; status: authorised.
02
Drugs
Recombinant human plasma gelsolin
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2023-510109-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510109-16-00.